Leadership

Effective corporate governance is the foundation of our mission.

Arrow Down Icon

Jurgis Auzins


Chief Executive Officer

Jurgis Auzins is the Chief Executive Officer and the founder of Rigvir Group, a rapidly growing biotechnological company, specializing in manufacturing and global marketing of Oncolytic Virotherapy medication, representing Prof. Aina Muceniece’s family. Mr. Auzins is the majority shareholder of the company and the main influencer in the business operations and strategic directions. His leadership has provided expanding product registration system, rapid development, growth, and worldwide recognition for Rigvir Group.

“We are committed to provide access to virotherapy for everyone around the world.”


Jurgis Auzins

Chief Executive Officer, Rigvir Group

Ivars Kalvins


Head of Scientific Council

Ivars Kalvins, Dr.habil.chem., is Head of the Scientific Council at Rigvir Group. Professor Ivars Kalvins has gained international recognition as the author of several hundred publications, more than 550 patents, including on development of anticancer compounds and immunomodulators, like Belinostat, a histone deacetylase inhibitor drug, for the treatment of hematological malignancies and solid tumors. Also, his effort has brought to the market one of the most efficient and successful medications against heart disease - meldonium (Mildronate).

He is a Full Member of the Latvian Academy of Sciences, Member of the European Academy of Sciences and Arts, Chairman of the Scientific Council of the Latvian Institute of Organic Synthesis, Head of the Division of Medical Chemistry since 1992, and Head of the Laboratory of Carbofunctional Connections.

Professor Kalvins was one of the three finalists nominated for the European Inventor Award in the lifetime achievement category in 2015.

“There is no untreatable disease, there is untreatable thinking. If a disease mechanism is known, a treatment can be found. It’s just a matter of time and effort.”


Ivars Kalvins

Head of Scientific Council, Rigvir Group

Kristine Juckovica


Chief Operating Officer

Kristine Juckovica is Chief Operating Officer of Rigvir Group. Mrs. Juckovica is responsible for internal processes of human resources and communication. She also leads all marketing and public relations functions, including the communication with state institutions and regulators.

Prior to joining Rigvir Group in 2016, Mrs. Juckovica served as a Member of the Bord at The Pharmacy Development Association and Public Policy Manager at Euroaptieka, one of the largest pharmaceutical wholesale and retail companies in the Baltic region. She has more than 10 years of experience holding various management roles in the public sector, with a prior leading position as Head of Ministers office at the Ministry of Health of the Republic of Latvia.

Mrs. Juckovica has received a master’s degree in Public Administration (MPA).

“Impossible is not a fact. It's an opinion.”


Kristine Juckovica

Chief Operating Officer, Rigvir Group

Peteris Alberts, Assoc. Prof., PhD


Head of Research and Development

Peteris Alberts is leading the department of Research & Development of Rigvir Group.

He previously served as a Senior Scientist at Evolva. Dr. Alberts also held other leading scientific positions at LifeCycle Pharma, Stricent, Maxygen, and Pharmacia & Upjohn, Biovitrum.

Since earning his PhD in Karolinska Institute, he has authored numerous publications and was awarded as Honorary Doctor of Medicine from Latvian Academy of Sciences.

“It is always important for me to find out the truth.”


Prof. Peteris Alberts

Head of Research and Development, Rigvir Group

Karlis Urbans


Head of Business Development

Karlis Urbans, MBA, is Head of Business Development of Rigvir Group. Mr. Urbans is a business development professional with financial background in KPMG and as CFO for more than 10 years.

Since restructuring to the format of Biotechnological Company, he is leading the process for development of new collaborations and strategic partnerships, including attraction of investment and public funding, to facilitate the development and availability of unique cancer virotherapy medicine worldwide.

“Advancement is possible only through problem solving.”


Karlis Urbans

Head of Business Development, Rigvir Group